|
1
|
Stojnev S, Conic I, Ristic Petrovic A, Petkovic I, Radic M, Krstic M, Jankovic Velickovic L. The Association of Death Receptors and TGF-β1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance. Biomedicines 2024; 12:1123. [PMID: 38791085 PMCID: PMC11117556 DOI: 10.3390/biomedicines12051123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Revised: 05/12/2024] [Accepted: 05/15/2024] [Indexed: 05/26/2024] Open
Abstract
Death receptor signalization that triggers the extrinsic apoptotic pathway and TGF-β1 have important roles in urothelial carcinogenesis, with a complex interplay between them. The aim of this research was to assess the association of death receptors DR4, DR5, and FAS as well as TGF-β1 immunohistochemical expression with the clinicopathological characteristics of urothelial bladder cancer (UBC) and to evaluate their prognostic significance. The decrease or loss of death receptors' expression was significantly associated with muscle-invasive tumors, while non-invasive UBC often retains the expression of death receptors, which are mutually strongly linked. High DR4 expression is a marker of low-grade tumors and UBC associated with exposition to known carcinogens. Conversely, TGF-β1 was significantly associated with high tumor grade and advanced stage. High expression of DR4 and FAS indicates longer overall survival. High TGF-β1 signifies an inferior outcome and is an independent predictor of adverse prognosis in UBC patients. This study reveals the expression profile of death receptors in UBC and their possible interconnection with TGF-β1 and indicates independent prognostic significance of high FAS and TGF-β1 expression in UBC, which may contribute to deciphering the enigma of UBC heterogeneity in light of the rapid development of novel and effective therapeutic approaches, including targeting of the TRAIL-induced apoptotic pathway.
Collapse
Affiliation(s)
- Slavica Stojnev
- Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia
- Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Irena Conic
- Clinic of Oncology, University Clinical Center Nis, 18000 Nis, Serbia; (I.C.)
- Department of Oncology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Ana Ristic Petrovic
- Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia
- Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Ivan Petkovic
- Clinic of Oncology, University Clinical Center Nis, 18000 Nis, Serbia; (I.C.)
- Department of Oncology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Milica Radic
- Clinic of Oncology, University Clinical Center Nis, 18000 Nis, Serbia; (I.C.)
- Department of Oncology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Miljan Krstic
- Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia
- Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| | - Ljubinka Jankovic Velickovic
- Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia
- Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
| |
Collapse
|
|
2
|
Singh D, Tewari M, Singh S, Narayan G. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy. Future Oncol 2021; 17:581-596. [PMID: 33401962 DOI: 10.2217/fon-2020-0727] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, can induce apoptosis in cancer cells, sparing normal cells when bound to its associated death receptors (DR4/DR5). This unique mechanism makes TRAIL a potential anticancer therapeutic agent. However, clinical trials of recombinant TRAIL protein and TRAIL receptor agonist monoclonal antibodies have shown disappointing results due to its short half-life, poor pharmacokinetics and the resistance of the cancer cells. This review summarizes TRAIL-induced apoptotic and survival pathways as well as mechanisms leading to apoptotic resistance. Recent development of methods to overcome cancer cell resistance to TRAIL-induced apoptosis, such as protein modification, combination therapy and TRAIL-based gene therapy, appear promising. We also discuss the challenges and opportunities in the development of TRAIL-based therapies for the treatment of human cancers.
Collapse
Affiliation(s)
- Deepika Singh
- Department of Molecular & Human Genetics, Cancer Genetics Laboratory, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Mallika Tewari
- Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India
| | - Sunita Singh
- Department of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, 221005, India
| | - Gopeshwar Narayan
- Department of Molecular & Human Genetics, Cancer Genetics Laboratory, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| |
Collapse
|
|
3
|
Lee WH, Han MW, Kim SH, Seong D, An JH, Chang HW, Kim SY, Kim SW, Lee JC. Tristetraprolin Posttranscriptionally Downregulates TRAIL Death Receptors. Cells 2020; 9:cells9081851. [PMID: 32784606 PMCID: PMC7465502 DOI: 10.3390/cells9081851] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 07/31/2020] [Accepted: 08/04/2020] [Indexed: 12/30/2022] Open
Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has attracted attention as a potential candidate for cancer therapy. However, many primary cancers are resistant to TRAIL, even when combined with standard chemotherapy. The mechanism of TRAIL resistance in cancer cells has not been fully elucidated. The TRAIL death receptor (DR) 3′-untranslated region (3′-UTR) is reported to contain AU-rich elements (AREs) that are important for regulating DR mRNA stability. However, the mechanisms by which DR mRNA stability is determined by its 3′-UTR are unknown. We demonstrate that tristetraprolin (TTP), an ARE-binding protein, has a critical function of regulating DR mRNA stability. DR4 mRNA contains three AREs and DR5 mRNA contains four AREs in 3′-UTR. TTP bound to all three AREs in DR4 and ARE3 in DR5 and enhanced decay of DR4/5 mRNA. TTP overexpression in colon cancer cells changed the TRAIL-sensitive cancer cells to TRAIL-resistant cells, and down-regulation of TTP increased TRAIL sensitivity via DR4/5 expression. Therefore, this study provides a molecular mechanism for enhanced levels of TRAIL DRs in cancer cells and a biological basis for posttranscriptional modification of TRAIL DRs. In addition, TTP status might be a biomarker for predicting TRAIL response when a TRAIL-based treatment is used for cancer.
Collapse
Affiliation(s)
- Won Hyeok Lee
- Department of Otorhinolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea; (W.H.L.); (M.W.H.); (S.H.K.); (D.S.); (J.H.A.)
- Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea
| | - Myung Woul Han
- Department of Otorhinolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea; (W.H.L.); (M.W.H.); (S.H.K.); (D.S.); (J.H.A.)
- Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea
| | - Song Hee Kim
- Department of Otorhinolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea; (W.H.L.); (M.W.H.); (S.H.K.); (D.S.); (J.H.A.)
- Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea
| | - Daseul Seong
- Department of Otorhinolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea; (W.H.L.); (M.W.H.); (S.H.K.); (D.S.); (J.H.A.)
- Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea
| | - Jae Hee An
- Department of Otorhinolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea; (W.H.L.); (M.W.H.); (S.H.K.); (D.S.); (J.H.A.)
- Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea
| | - Hyo Won Chang
- Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; (H.W.C.); (S.Y.K.)
| | - Sang Yoon Kim
- Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; (H.W.C.); (S.Y.K.)
| | - Seong Who Kim
- Department of Biochemistry and Molecular Biology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
- Correspondence: (S.W.K.); (J.C.L.); Tel.: +82-2-3010-4270 (S.W.K.); +82-33-610-4372 (J.C.L.); Fax: +82-2-3010-4249 (S.W.K.); +82-33-642-3189 (J.C.L.)
| | - Jong Cheol Lee
- Department of Otorhinolaryngology, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Korea
- Correspondence: (S.W.K.); (J.C.L.); Tel.: +82-2-3010-4270 (S.W.K.); +82-33-610-4372 (J.C.L.); Fax: +82-2-3010-4249 (S.W.K.); +82-33-642-3189 (J.C.L.)
| |
Collapse
|